Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Efegatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 6/20 | 0.46 |
| ▸ | OPRK1 known ✓ | P41145 | 6/20 | 0.46 |
| ▸ | F2 | P00734 | 5/20 | 0.56 |
| ▸ | PLG | P00747 | 2/20 | 0.56 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.46 |
| ▸ | XIAP | P98170 | 4/20 | 0.46 |
| ▸ | EPHA2 | P29317 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Efegatran SCHEMBL7273879 | 1.00 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL7264662 | 1.00 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL1229047 | 0.99 | F2 (0.55) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL635674 | 0.97 | F2 (0.58) | F2PLGPRSS1XIAPOPRM1 | |
| Efegatran SCHEMBL7412481 | 0.94 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Sulfuric Acid SCHEMBL7264554 | 0.93 | F2 (0.54) | F2PLGPRSS1XIAPOPRM1 | |
| Sulfuric Acid SCHEMBL7265422 | 0.91 | F2 (0.53) | F2PLGPRSS1XIAPOPRM1 | |
| SCHEMBL7446078 | 0.91 | F2 (0.56) | F2PLGPRSS1XIAPOPRM1 | |
| Sulfuric Acid SCHEMBL7270900 | 0.91 | F2 (0.52) | F2PLGPRSS1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL7414568 | 0.90 | F2 (0.55) | F2PLGPRSS1XIAPOPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 856 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| CN-109893528-A | Koumine treats the purposes of disorders of lipid metabolism and its related disease or illness | 福建医科大学 | 2019-06-18 | — | — | CN | claimed |
| WO-2014039859-A1 | DIAGNOSTIC MARKERS FOR PLATELET FUNCTION AND METHODS OF USE | DUKE UNIVERSITY (US) | 2014-03-13 | — | — | WO | claimed |
| EP-2305639-A2 | Organic compounds | Novartis AG (CH) | 2011-04-06 | — | — | EP | claimed |
| US-20100008913-A1 | Methods and compositions for treating platelet-related disorders | HANSON, STEPHEN R. | 2010-01-14 | — | — | US | claimed |
| US-20080113024-A1 | Methods and compositions for treating platelet-related disorders | COMERICA BANK | 2008-05-15 | — | — | US | claimed |
| EP-1363668-B1 | COMBINATIONS OF BILE ACID SEQUESTRANT(S) AND STEROL ABSORPTION INHIBITOR(S) AND TREATMENTS FOR VASCULAR INDICATIONS | SCHERING CORP (US) | 2007-08-15 | — | — | EP | claimed |
| EP-1810693-A2 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | Shering Corporation (US) | 2007-07-25 | — | — | EP | claimed |
| EP-1785144-A2 | Combinations of bile acids sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications | Shering Corporation (US) | 2007-05-16 | — | — | EP | claimed |
| US-20050228001-A1 | Methods and compositions for treating platelet-related disorders | COMERICA BANK | 2005-10-13 | — | — | US | claimed |
| CN-1658903-A | Combinations of peroxisome proliferator-activated receptor (ppar) activator(s) and sterol absorption inhibitor(s) and treatments for vascular indications | SCHERING CORP (US) | 2005-08-24 | — | — | CN | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-5250660-A | Peptide purification process | ELI LILLY AND COMPANY (US) | 1993-10-05 | — | — | US | claimed |
| EP-0185390-B1 | TRIPEPTIDYL-ARGININALDEHYDE, PROCESS FOR ITS PREPARATION AND MEDICAMENTS THEREOF, AS WELL AS N-(MONOALKYL) AND N,N-DI-(ALKYL)-XXX-L-PROLINE DIPEPTIDE | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1991-10-02 | — | — | EP | claimed |
| US-4703036-A | ANTICOAGULANTS | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1987-10-27 | — | — | US | claimed |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | disclosed |
| US-4703036-A | ANTICOAGULANTS | RICHTER GEDEON VEGYESZETI GYAR RT (HU) | 1987-10-27 | — | — | US | disclosed |
| EP-0185390-A2 | Tripeptidyl-argininaldehyde, process for its preparation and medicaments thereof, as well as N-(monoalkyl) and N,N-di-(alkyl)-Xxx-L-proline dipeptide | RICHTER GEDEON VEGYESZETI GYAR R.T. (HU) | 1986-06-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | OPRM1 4426/4885OPRK1 4022/4885F2 314/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | OPRM1 3687/4885OPRK1 2555/4885F2 4700/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.